BACKGROUND & AIMS: T-cell immunoglobulin mucin (TIM) genes are expressed by T cells and regulate host immunity and tolerance. CD4(+) T cells mediate innate immunity-dominated liver ischemia-reperfusion injury (IRI) by unknown mechanisms. TIM-1 is involved in liver IRI, which is activated in part by the Toll-like receptor (TLR)4; we investigated the role of TIM-3 and TLR4 in IRI. METHODS: Using an antibody against TIM-3 (anti-TIM-3), we studied TIM-3 signaling in mice following partial warm liver ischemia and reperfusion. RESULTS: Mice given anti-TIM-3 had more liver damage than controls. Histological studies revealed that anti-TIM-3 increased hepatocellular damage and local neutrophil infiltration, facilitated local accumulation of T cells and macrophages, and promoted liver cell apoptosis. Intrahepatic neutrophil activity; induction of proinflammatory cytokines and chemokines; and expression of cleaved caspase-3, nuclear factor-κB, and TLR4 all increased in mice given anti-TIM-3. Administration of anti-TIM-3 followed by anti-galectin-9 (Gal-9 is a TIM-3 ligand) increased production of interferon-γ by concanavalin A (ConA)-stimulated spleen T cells and expression of tumor necrosis factor-α and interleukin-6 in ConA-stimulated macrophages co-cultured with T cells. Anti-TIM-3 did not affect liver IRI in TLR4-deficient mice. CONCLUSION: TIM-3 blockade exacerbated local inflammation and liver damage, indicating the importance of TIM-3-Gal-9 signaling in maintaining hepatic homeostasis. TIM-3-TLR4 cross-regulation determined the severity of liver IRI in TLR4-dependent manner; these findings provide important information about the modulation of innate vs adaptive responses in patients that received liver transplants. Negative co-stimulation signaling by hepatic T-cells might be developed to minimize innate immunity-mediated liver tissue damage.
BACKGROUND & AIMS: T-cell immunoglobulin mucin (TIM) genes are expressed by T cells and regulate host immunity and tolerance. CD4(+) T cells mediate innate immunity-dominated liver ischemia-reperfusion injury (IRI) by unknown mechanisms. TIM-1 is involved in liver IRI, which is activated in part by the Toll-like receptor (TLR)4; we investigated the role of TIM-3 and TLR4 in IRI. METHODS: Using an antibody against TIM-3 (anti-TIM-3), we studied TIM-3 signaling in mice following partial warm liver ischemia and reperfusion. RESULTS:Mice given anti-TIM-3 had more liver damage than controls. Histological studies revealed that anti-TIM-3 increased hepatocellular damage and local neutrophil infiltration, facilitated local accumulation of T cells and macrophages, and promoted liver cell apoptosis. Intrahepatic neutrophil activity; induction of proinflammatory cytokines and chemokines; and expression of cleaved caspase-3, nuclear factor-κB, and TLR4 all increased in mice given anti-TIM-3. Administration of anti-TIM-3 followed by anti-galectin-9 (Gal-9 is a TIM-3 ligand) increased production of interferon-γ by concanavalin A (ConA)-stimulated spleen T cells and expression of tumornecrosis factor-α and interleukin-6 in ConA-stimulated macrophages co-cultured with T cells. Anti-TIM-3 did not affect liver IRI in TLR4-deficientmice. CONCLUSION:TIM-3 blockade exacerbated local inflammation and liver damage, indicating the importance of TIM-3-Gal-9 signaling in maintaining hepatic homeostasis. TIM-3-TLR4 cross-regulation determined the severity of liver IRI in TLR4-dependent manner; these findings provide important information about the modulation of innate vs adaptive responses in patients that received liver transplants. Negative co-stimulation signaling by hepatic T-cells might be developed to minimize innate immunity-mediated liver tissue damage.
Authors: Ana C Anderson; David E Anderson; Lisa Bregoli; William D Hastings; Nasim Kassam; Charles Lei; Rucha Chandwaskar; Jozsef Karman; Ee W Su; Mitsuomi Hirashima; Jeffrey N Bruce; Lawrence P Kane; Vijay K Kuchroo; David A Hafler Journal: Science Date: 2007-11-16 Impact factor: 47.728
Authors: Silke M Schulz; Gabriele Köhler; Christoph Holscher; Yoichiro Iwakura; Gottfried Alber Journal: Int Immunol Date: 2008-07-03 Impact factor: 4.823
Authors: Sylvia Frisancho-Kiss; Sarah E Davis; Jennifer F Nyland; J Augusto Frisancho; Daniela Cihakova; Masheka A Barrett; Noel R Rose; Delisa Fairweather Journal: J Immunol Date: 2007-06-01 Impact factor: 5.422
Authors: Sung-Chun Tang; Thiruma V Arumugam; Xiangru Xu; Aiwu Cheng; Mohamed R Mughal; Dong Gyu Jo; Justin D Lathia; Dominic A Siler; Srinivasulu Chigurupati; Xin Ouyang; Tim Magnus; Simonetta Camandola; Mark P Mattson Journal: Proc Natl Acad Sci U S A Date: 2007-08-10 Impact factor: 11.205
Authors: Ying Ju; Nan Hou; Xiao Ning Zhang; Di Zhao; Ying Liu; Jin Jin Wang; Fang Luan; Wei Shi; Fa Liang Zhu; Wen Sheng Sun; Li Ning Zhang; Cheng Jiang Gao; Li Fen Gao; Xiao Hong Liang; Chun Hong Ma Journal: Cell Mol Immunol Date: 2009-02 Impact factor: 11.530
Authors: Benjamin H Friedman; Joshua H Wolf; Liqing Wang; Mary E Putt; Abraham Shaked; Jason D Christie; Wayne W Hancock; Kim M Olthoff Journal: Liver Transpl Date: 2012-02 Impact factor: 5.799
Authors: Haofeng Ji; Yu Zhang; Xiu-da Shen; Feng Gao; Cynthia Y Huang; Catalina Abad; Ronald W Busuttil; James A Waschek; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2013-01-18 Impact factor: 17.425
Authors: Bibo Ke; Xiu-Da Shen; Haofeng Ji; Naoko Kamo; Feng Gao; Maria Cecilia S Freitas; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: J Hepatol Date: 2011-07-12 Impact factor: 25.083
Authors: J M Diamond; D J Lederer; S M Kawut; J Lee; V N Ahya; S Bellamy; S M Palmer; V N Lama; S Bhorade; M Crespo; E Demissie; J Sonett; K Wille; J Orens; P D Shah; A Weinacker; D Weill; B A Kohl; C C Deutschman; S Arcasoy; A S Shah; J A Belperio; D Wilkes; J M Reynolds; L B Ware; J D Christie Journal: Am J Transplant Date: 2011-08-22 Impact factor: 8.086
Authors: Kojiro Nakamura; Shoichi Kageyama; Bibo Ke; Takehiro Fujii; Rebecca A Sosa; Elaine F Reed; Nakul Datta; Ali Zarrinpar; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Liver Transpl Date: 2017-10 Impact factor: 5.799
Authors: Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski Journal: Nat Rev Gastroenterol Hepatol Date: 2012-12-11 Impact factor: 46.802